Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Boehrer S, Gardin C, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: dreyfus f. Leukemia. 2011 Jul;25(7):1207-9. doi: 10.1038/leu.2011.63. Epub 2011 Apr 5. Leukemia. 2011. PMID: 21468040 No abstract available.
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: dreyfus f. Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494260
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Itzykson R, Thépot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: dreyfus f. Leuk Res. 2012 Apr;36(4):397-400. doi: 10.1016/j.leukres.2011.11.019. Epub 2011 Dec 15. Leuk Res. 2012. PMID: 22177456
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Kelaidi C, Park S, Brechignac S, Mannone L, Vey N, Dombret H, Aljassem L, Stamatoullas A, Adès L, Giraudier S, de Botton S, Raynaud S, Lepelley P, Picard F, Leroux G, Daniel MT, Bouscary D, Dreyfus F, Fenaux P; Groupe Francophone des Myélodysplasies (GFM). Kelaidi C, et al. Among authors: dreyfus f. Leuk Res. 2008 Jul;32(7):1049-53. doi: 10.1016/j.leukres.2007.11.037. Epub 2008 Jan 11. Leuk Res. 2008. PMID: 18191202
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
Tamburini J, Elie C, Park S, Beyne-Rauzy O, Gardembas M, Berthou C, Mahe B, Sanhes L, Stamatoullas A, Vey N, Aouba A, Slama B, Quesnel B, Vekhoff A, Sotto JJ, Vassilief D, Al-Nawakil C, Fenaux P, Dreyfus F, Bouscary D; Groupe Francophone des Myélodysplasies, GFM. Tamburini J, et al. Among authors: dreyfus f. Leuk Res. 2009 Apr;33(4):547-50. doi: 10.1016/j.leukres.2008.06.005. Epub 2008 Jul 21. Leuk Res. 2009. PMID: 18640718 Clinical Trial. No abstract available.
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N, Suarez F, Beyne-Rauzy O, Guerci A, Cheze S, Thomas X, Stamatoullas A, Gardembas M, Bauduer F, Kolb A, Chaury MC, Legros L, Damaj G, Chermat F, Dreyfus F, Fenaux P, Ades L; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: dreyfus f. Leukemia. 2009 Apr;23(4):673-8. doi: 10.1038/leu.2008.362. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151787 Clinical Trial.
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.
Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, Stamatoullas A, Choufi B, Delaunay J, Gourin MP, Cheze S, Ravoet C, Ferrant A, Escoffre-Barbe M, Aljassem L, Raffoux E, Itzykson R, Adès L, Dreyfus F, Fenaux P. Kelaidi C, et al. Among authors: dreyfus f. Leukemia. 2013 Jun;27(6):1283-90. doi: 10.1038/leu.2013.16. Epub 2013 Jan 16. Leukemia. 2013. PMID: 23370672
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U; International Working Group on MDS with del(5q). Kuendgen A, et al. Leukemia. 2013 Apr;27(5):1072-9. doi: 10.1038/leu.2012.369. Epub 2012 Dec 21. Leukemia. 2013. PMID: 23257782 Free PMC article.
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.
Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M. Kosmider O, et al. Among authors: dreyfus f. Leukemia. 2010 May;24(5):1094-6. doi: 10.1038/leu.2010.52. Epub 2010 Apr 8. Leukemia. 2010. PMID: 20376084 No abstract available.
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F. Park S, et al. Among authors: dreyfus f. Leuk Res. 2011 Nov;35(11):1530-3. doi: 10.1016/j.leukres.2011.07.007. Epub 2011 Jul 30. Leuk Res. 2011. PMID: 21803419
258 results